• Blog
  • Human Microbiome Market Report

    Human Microbiome Market Report

    Human Microbiome Market Report
    Report code - SRHL245 Delivery - 2 Weeks
    Get Free Sample |
    Play Audio
    Listen
    Global Human Microbiome Market, Dynamics, Market Analysis
    See more...

    Impact of COVID-19 on Human Microbiome Market

    Covid-19 has impacted the market dynamics, competition, and global...

    See more...

    Impact of COVID-19 on Human Microbiome Market

    Covid-19 has impacted the market dynamics, competition, and global supply chain. The revenues have gone down in 2020 and may resume an uptrend gradually from 2021. Companies optimizing their operation and strategy will sustain and beat the competition.

    Note: The summary below might not have included insights on covid impact since we have large number of reports.

    Market Insights

    The Global Human Microbiome Market is projected to grow from USD 520.5 million in 2020 to USD 1,822.3 million by 2026 at a CAGR of over 23.2% during the forecast period.

    Figure: Global Human Microbiome Market Size, 2020-2026 (USD Million)

    Human-Microbiome-Market-Forecast

    Want to know segmentation details? Register Here

    What are Human Microbiomes?

    Human tissues are covered with millions of microorganisms such as viruses, bacteria, and fungi, which are known as human microbiota. All the genes present inside these organisms are called as microbiome. Human microbiomes play a vital role in advanced healthcare, as it enables to allow easy digestion of food, production of vitamins such as Vitamin K, B, and B12 which is important for blood coagulation. These microbiomes improves human nutrition and immunity.

    Key Players

    Key players operating in the global human microbiome market are

    • ENTEROME (France),
    • Yakult (Japan),
    • DuPont de Nemours, Inc. (The U.S),
    • Metabiomics Corporation (The U.S),
    • ViThera Pharmaceuticals, Inc. (The U.S),
    • Second Genome Inc. (The U.S),
    • MICROBIOME THERAPEUTICS LLC (The U.S),
    • Vedanta Biosciences, Inc. (The U.S),
    • Osel, Inc. (The U.S),
    • Merck Sharp & Dohme Corp (The U.S),
    • Seres Therapeutics (The U.S), and
    • Synthetic Biologics, Inc. (The U.S).

    Market Dynamics

    Growing prevalence of C. Difficile infection (CDI) is a key factor driving the demand for human microbiome.

    • Furthermore, the introduction of probiotics is expected to bring change in intestinal microbiota and can stabilize microbial communities, thus can prevent gut inflammation, boosting the growth of the human microbiome market.
    • Moreover, rising collaborations between public-private organizations offer immense opportunities to the market players. However, government regulations are expected to restrain product consumption in the following years.

    Segment Analysis

    Application Trends

    Based on application, the global human microbiome market has been bifurcated into therapeutics and diagnostics.

    • Under these, the therapeutics segment held the largest market share in 2020 and is likely to register a substantial CAGR in the following years.
    • This is mainly attributed to increase in R&D funding into microbiome-based therapies and technological advancements, which promulgates the segment growth.

    Regional Trends

    By region, the North America market garnered the highest market share in 2020 and is projected to grow at a healthy CAGR during the assessment period.

    • This is mainly attributed to the increasing incidences of lifestyle-related diseases and autoimmune disorders in this region.
    • Also, presence of a strong drug pipeline further boosts the regional growth.
    • The US is the largest contribution to the regional market growth due to increasing standard of living and high medical expenditure.

    COVID-19 Impact on Global Human Microbiome Market

    The COVID-19 pandemic has adversely affected the human microbiome industry including their preclinical studies and clinical trials of microbiome-based therapeutics and diagnostics products. Furthermore, the COVID-19 pandemic has focused the need for manufacturing companies and R&D organizations to collaborate with the government to innovate therapeutics and diagnostics, to meet future health crises. Several universities and major market players are focusing on developing interventions for coronavirus.

    Critical Questions Answered in the Report

    • What are the key trends in the global human microbiome market?
    • How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in next five years?
    • What is the impact of COVID-19 on global human microbiome market?
    • What are the key strategies adopted by the major vendors to lead in the global human microbiome market?
    • What is the market share of the top vendors?

    Want to know the full scope of the report? Register Here

    Target Audience

    The following is a list of the customers that the Human Microbiome market aims to convert the most:

    • Human microbiome companies
    • Human microbiome vendors
    • R&D organizations
    • Hospitals
    • Government organizations

    Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected].

    Frequently Asked Questions (FAQs)

    The human microbiome market size is expected to reach USD 1,822.3 million in the foreseeable future.

    The human microbiome market is expected to witness an impressive growth of 23.2% CAGR in the foreseeable future.

    ENTEROME (France), Yakult (Japan), DuPont de Nemours, Inc. (The U.S), Metabiomics Corporation (The U.S), ViThera Pharmaceuticals, Inc. (The U.S), Second Genome Inc. (The U.S), MICROBIOME THERAPEUTICS LLC (The U.S), Vedanta Biosciences, Inc. (The U.S), Osel, Inc. (The U.S), Merck Sharp & Dohme Corp (The U.S), Seres Therapeutics (The U.S) and Synthetic Biologics, Inc. (The U.S) are among the key players in the human microbiome market.

    North America garnered the largest share of human microbiome market in 2020.

    The therapeutics segment held the largest share of human microbiome market in 2020.

    Growing prevalence of C. Difficile infection, the introduction of probiotics, rising collaborations between public-private organizations are the factors driving the growth of human microbiome market.

    Human microbiome companies, Human microbiome vendors, R&D organizations, Hospitals, Government organizations are the target audience in the human microbiome market.

    •